跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
張 鴻猷
專案助理教授
醫學系內科學科
電子郵件
amadeus0814
ym.edu
tw
h-index
h10-index
h5-index
1602
引文
23
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
707
引文
14
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
487
引文
11
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
2009
2024
每年研究成果
概覽
指紋
網路
研究成果
(79)
類似的個人檔案
(6)
指紋
查看啟用 Hung-Yu Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Atrial Fibrillation
91%
Catheter Ablation
82%
Heart Failure with Preserved Ejection Fraction (HFpEF)
67%
Sacubitril-valsartan
66%
Reduced Ejection Fraction
56%
Heart Failure
45%
Heart Failure Patients
44%
Taiwan
44%
Patients with Heart Failure
35%
Taiwan Society of Cardiology
34%
Clinical Outcomes
29%
Left Ventricular Ejection Fraction
27%
Ablation
27%
Heart Failure Hospitalization
26%
Superior Vena Cava
24%
Atrial Fibrillation Ablation
23%
Ivabradine
23%
Atrial Arrhythmia
19%
Cardiovascular Mortality
19%
Non-paroxysmal Atrial Fibrillation
17%
Atrial Substrate
16%
Angiotensin Receptor-neprilysin Inhibitor
16%
Ganglionated Plexi
16%
Heart Failure Treatment
15%
Confidence Interval
15%
Left Atrial
15%
Heart Transplantation
14%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
13%
Baseline Characteristics
13%
Substrate Properties
12%
CHA2DS2-VASc Score
12%
Cardiac Resynchronization Therapy
12%
All-cause Mortality
12%
Heart Disease Diagnosis
11%
Cardiovascular Outcomes
11%
Paroxysmal Atrial Fibrillation
11%
Atrium
11%
Heart Rate
11%
Hospitalization
11%
Taiwanese
10%
Clinical Efficacy
10%
Systolic Heart Failure
10%
Cost-effectiveness Evaluation
10%
Sleep Apnea Detection
10%
Health Systems
10%
Cardiac Autonomic Function
10%
Sudden Cardiac Death
10%
Real-world Experience
10%
Angiotensin
10%
Atrial Flutter
10%
Medicine and Dentistry
Atrial Fibrillation
100%
Congestive Heart Failure
91%
Ablation
85%
Heart Failure with Reduced Ejection Fraction
49%
Ejection Fraction
42%
Cardiology
36%
Sacubitril
35%
Valsartan
35%
Recurrent Disease
25%
Drug Therapy
22%
Superior Vena Cava
20%
Tachyarrhythmia
16%
Angiotensin Receptor
16%
Health Care Cost
16%
Atrial Flutter
15%
Electrocardiography
15%
Combination Therapy
14%
Cost-Effectiveness Analysis
14%
Heart Transplantation
13%
Cardiovascular System
13%
Cardiac Resynchronization Therapy
12%
Enkephalinase Inhibitor
12%
Heart Left Ventricle Ejection Fraction
12%
Ivabradine
11%
Atrium
11%
Paroxysmal Atrial Fibrillation
10%
Electrography
10%
ST Segment Elevation Myocardial Infarction
10%
Systolic Heart Failure
10%
Angiotensin
10%
Mortality Rate
10%
Diabetes
10%
Electrocardiogram
10%
Chronic Kidney Disease
9%
Prevalence
9%
Glycon
9%
Pulmonary Vein Isolation
8%
Apoplexy
8%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Hazard Ratio
8%
Persistent Atrial Fibrillation
8%
All Cause Mortality
8%
Sudden Cardiac Death
7%
Supraventricular Tachycardia
7%
Antiarrhythmic Agent
7%
Cardiovascular Risk
7%
Sudden Death
6%
Heart Surgery
6%
CHA2DS2-VASc Score
6%
CHADS2 Score
6%